Comment from Muscular Dystrophy Association

Summary: The Muscular Dystrophy Association (MDA) supports the FDA's initiative on drug repurposing, specifically advocating for neuromuscular diseases to be prioritized as a key area of focus. They suggest specific pathways for identifying candidates and call for collaboration with CMS and HHS to reduce insurance and reimbursement barriers for off-label therapies.